OTLK - Outlook Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.5800
-0.0212 (-3.53%)
At close: 3:52PM EDT
Stock chart is not supported by your current browser
Previous Close0.6012
Open0.6176
Bid0.5701 x 800
Ask0.5898 x 1800
Day's Range0.5713 - 0.6240
52 Week Range0.4990 - 7.7100
Volume192,138
Avg. Volume754,508
Market Cap47.854M
Beta (5Y Monthly)-0.64
PE Ratio (TTM)N/A
EPS (TTM)-1.9230
Earnings DateMay 12, 2020 - May 17, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est7.13
  • Investors Who Bought Outlook Therapeutics (NASDAQ:OTLK) Shares Three Years Ago Are Now Down 98%
    Simply Wall St.

    Investors Who Bought Outlook Therapeutics (NASDAQ:OTLK) Shares Three Years Ago Are Now Down 98%

    As every investor would know, not every swing hits the sweet spot. But you want to avoid the really big losses like...

  • GlobeNewswire

    Outlook Therapeutics Announces LYTENAVA™ (bevacizumab-vikg), Anticipated Brand Name for ONS-5010, If Approved

    Outlook Therapeutics intends to market ONS-5010 as LYTENAVA™ (bevacizumab-vikg), if approved. LYTENAVA™ (bevacizumab-vikg), an investigational ophthalmic formulation of bevacizumab for retinal indications, is currently in two registration clinical trials (NORSE 1 and NORSE 2) to treat wet age-related macular degeneration (wet AMD). CRANBURY, N.J., March 05, 2020 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has received U.S. Food and Drug Administration (FDA) tentative approval of the Tradename for ONS-5010 as LYTENAVA™ (bevacizumab-vikg).

  • GlobeNewswire

    Outlook Therapeutics Announces Closing of $10.2 Million Financings Priced At-The-Market

    Outlook Therapeutics, Inc. (OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has closed its previously-announced registered direct offering priced at-the-market under Nasdaq rules of 7,598,426 shares of its common stock, at a combined purchase price of $1.016 per share and associated unregistered warrant, for aggregate gross proceeds of approximately $7.72 million. The Company also issued to the investors in the registered direct offering unregistered warrants to purchase up to an aggregate of 3,799,213 shares of its common stock. The warrants have an exercise price of $0.9535 per share of common stock, are exercisable on the date of issuance, and will expire four years following the date of issuance.

  • ACCESSWIRE

    SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Outlook Therapeutics, Inc.-OTLK

    NEW YORK, NY / ACCESSWIRE / February 25, 2020 / Levi & Korsinsky announces it has commenced an investigation of Outlook Therapeutics, Inc. (NASDAQ:OTLK) concerning possible breaches of fiduciary duty. ...

  • GlobeNewswire

    Outlook Therapeutics Announces $10.2 Million Financings Priced At-The-Market

    Outlook Therapeutics, Inc. (OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale in a registered direct offering priced at-the-market under Nasdaq rules, of 7,598,426 shares of its common stock, at a combined purchase price of $1.016 per share and associated unregistered warrant, for aggregate gross proceeds of approximately $7.72 million. The Company also agreed to issue to the investors in the registered direct offering unregistered warrants to purchase up to an aggregate of 3,799,213 shares of its common stock.

  • GlobeNewswire

    INVESTOR ALERT: Fields Kupka & Shukurov LLP Is Investigating Outlook Therapeutics, Inc. for Potential Securities Violations and Breach of Fiduciary Duty Claims.

    NEW YORK, Feb. 18, 2020 -- Fields Kupka & Shukurov LLP is investigating potential securities violations and breach of fiduciary duty claims involving the board of directors.

  • GlobeNewswire

    Outlook Therapeutics Provides Business Update and Reports Financial Results for the First Quarter of Fiscal Year 2020

    CRANBURY, N.J., Feb. 14, 2020 -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first.

  • GlobeNewswire

    Outlook Therapeutics to Present at the 2020 BIO CEO & Investor Conference

    CRANBURY, N.J., Feb. 04, 2020 -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”),  a late clinical-stage biopharmaceutical company working to develop the first.

  • GlobeNewswire

    Outlook Therapeutics Announces Agreements to Streamline Capital Structure and Regain 100% Ownership of Any Future Net Profits for ONS-5010

    Outlook Therapeutics, Inc. (OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has entered into agreements with BioLexis Pte. Ltd. (“BioLexis”), its largest stockholder, and MTTR, LLC (“MTTR”), its development partner for ONS-5010, to better align the interests of all parties with the Company’s common stockholders and support the continued development of ONS-5010.

  • GlobeNewswire

    Outlook Therapeutics Announces Completion of Warrant Restructuring

    CRANBURY, N.J., Dec. 26, 2019 -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first.

  • GlobeNewswire

    Outlook Therapeutics Announces Warrant Amendment and Restructuring of Senior Secured Notes in Separate Transactions

    Outlook Therapeutics, Inc. (OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has taken action to improve the Company’s balance sheet through two separate transactions. Effective December 23, 2019, with consent of the required holders of the Outlook Therapeutics warrants issued in April 2019 (the “Warrants”) in an underwritten public offering, the Company amended the Warrants to reduce the exercise price to $0.232 per warrant and allow for the immediate exercise of the Warrants.

  • GlobeNewswire

    Outlook Therapeutics Provides Business Update and Reports Financial Results for Fiscal Year 2019

    Topline results from the NORSE 1 study of ONS-5010 expected to be announced in the third quarter of calendar 2020Enrollment in the NORSE 2 study underwaySPA agreement reached.

  • GlobeNewswire

    Outlook Therapeutics Receives FDA Agreement for Three Special Protocol Assessments for Additional Planned Clinical Trials of ONS-5010

    ONS-5010, an investigational ophthalmic formulation of bevacizumab for retinal indications, is currently in two clinical trials to treat wet age-related macular degeneration (wet AMD – NORSE 1 and 2). SPAs for clinical trial protocols for NORSE 4 for branch retinal vein occlusion (“BRVO”) and NORSE 5 and NORSE 6 for diabetic macular edema (“DME”) indicate FDA agreement on overall protocol design (entry criteria, dose selection, endpoints and planned analyses). CRANBURY, N.J., Dec. 03, 2019 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (OTLK) (the “Company”), a late clinical-stage biopharmaceutical company working to develop the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, today announced that it has received agreement from the U.S. Food and Drug Administration (“FDA”) on three Special Protocol Assessments (“SPAs”) for three additional registration clinical trials for its ongoing Phase 3 program for ONS-5010, an investigational ophthalmic formulation of bevacizumab.

  • What Kind Of Shareholders Own Outlook Therapeutics, Inc. (NASDAQ:OTLK)?
    Simply Wall St.

    What Kind Of Shareholders Own Outlook Therapeutics, Inc. (NASDAQ:OTLK)?

    A look at the shareholders of Outlook Therapeutics, Inc. (NASDAQ:OTLK) can tell us which group is most powerful...

  • GlobeNewswire

    Outlook Therapeutics to Present at the 29th Annual Ladenburg Thalmann 2019 Healthcare Conference

    CRANBURY, N.J., Sept. 11, 2019 -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”) today announced that it is scheduled to participate in the Ladenburg Thalmann 2019.

  • GlobeNewswire

    Outlook Therapeutics to Present at the H.C. Wainwright 21st Annual Healthcare Conference

    CRANBURY, N.J., Aug. 27, 2019 -- Outlook Therapeutics, Inc. (Nasdaq: OTLK) (the “Company”) today announced that it is scheduled to participate in the H.C. Wainwright 21st.

  • GlobeNewswire

    Outlook Therapeutics Completes Patient Enrollment for NORSE 1 a Phase 3 Clinical Trial for ONS-5010 in Wet AMD

    Outlook Therapeutics, Inc. (OTLK) (the “Company”), a late clinical-stage biopharmaceutical company focused on developing ONS-5010, an ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (wet AMD) and other retina diseases, today announced that it has completed patient enrollment in the NORSE 1 Phase 3 clinical trial, which is evaluating ONS-5010 against ranibizumab (Lucentis®) for wet AMD. “We are pleased with the building momentum in our two ongoing Phase 3 clinical trials for ONS-5010, including completing enrollment in NORSE 1. The study is the first of two ongoing, adequate and well controlled Phase 3 clinical trials evaluating ONS-5010 against ranibizumab for wet AMD.

  • GlobeNewswire

    Outlook Therapeutics Provides Business Update and Reports Financial Results for Third Quarter of Fiscal 2019

    CRANBURY, N.J., Aug. 14, 2019 -- Outlook Therapeutics, Inc. (NASDAQ: OTLK) (the “Company”) today reported business highlights and financial results for its third quarter ended.

  • GlobeNewswire

    Outlook Therapeutics Doses First Patient in the Second Phase 3 Clinical Trial for ONS-5010 in Wet AMD

    Outlook Therapeutics, Inc. (OTLK) (the “Company”), a late clinical-stage biopharmaceutical company focused on developing ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (wet AMD) and other retina diseases, today announced that it has dosed the first patient in the ONS-5010-002 Phase 3 clinical trial. “We are pleased to begin dosing patients in the ONS-5010-002 study, our second Phase 3 clinical trial for ONS-5010. This represents the achievement of another important milestone in our streamlined clinical and regulatory strategy, which is designed to support a Biologics License Application, or BLA, submission for ONS-5010 in wet AMD by the end of 2020,” said Lawrence A. Kenyon, President, Chief Executive Officer and Chief Financial Officer.

  • Hottest Wall Street Stories: What's Up, What's Down
    Zacks

    Hottest Wall Street Stories: What's Up, What's Down

    Tariff tantrums hit the broader stock markets last month, leading to the worst May after 2010. Below we discuss these in detail and the impact on the stock world from these events.

  • GlobeNewswire

    Outlook Therapeutics Signs Manufacturing Supply Agreement with FUJIFILM Diosynth Biotechnologies as Part of Commercialization Strategy for ONS-5010

    Outlook Therapeutics, Inc. (OTLK) (the “Company”), a late clinical-stage biopharmaceutical company focused on developing ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (wet AMD) and other retinal diseases, today announced that it has signed a master services agreement with FUJIFILM Diosynth Biotechnologies (FDB) for the production of ONS-5010. Under the terms of this agreement, FDB will provide global manufacturing of ONS-5010 to Outlook in support of the commercialization strategy for the drug.

  • GlobeNewswire

    Outlook Therapeutics Provides Business Update and Reports Second Quarter Financial Results for Fiscal 2019

    CRANBURY, N.J., May 15, 2019 -- Outlook Therapeutics, Inc. (NASDAQ:OTLK) (the “Company”) today reported business highlights and financial results for its second fiscal quarter.

  • GlobeNewswire

    Outlook Therapeutics Announces Addition of Jennifer M. Kissner, Ph.D. as Senior Vice President, Clinical Development

    Outlook Therapeutics, Inc. (OTLK) (the “Company”), a clinical-stage biopharmaceutical company focused on developing its lead clinical program, ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (wet AMD) and other retina diseases, today announced that Jennifer M. Kissner, Ph.D. has joined the Company as Senior Vice President, Clinical Development.

  • GlobeNewswire

    Outlook Therapeutics Announces Pricing of Public Offering of Common Stock and Warrants

    Outlook Therapeutics, Inc. (OTLK) (the “Company”) announced today the pricing of an underwritten public offering of 10,340,000 shares of its common stock, 15-month warrants to purchase up to an aggregate of 10,340,000 shares of common stock, and 5-year warrants to purchase up to an aggregate of 10,340,000 shares of common stock. BioLexis Pte. Ltd. (BioLexis), the Company’s strategic business partner and largest stockholder, led this financing with a $10 million investment. The shares of common stock and accompanying warrants are being sold at a combined public offering price of $2.75.